Home LiteratureArticle Details
PMID: 7884908 Published · ppublish English Journal Article Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.

DNA vaccination against persistent viral infection.

Journal of virology ·Vol. 69 ·No. 4 ·1995-04-00 ·Pages 2574-82

Martins LP, Lau LL, Asano MS, Ahmed R

Abstract

This study shows that DNA vaccination can confer protection against a persistent viral infection by priming CD8+ cytotoxic T lymphocytes (CTL). Adult BALB/c (H-2d) mice were injected intramuscularly with a plasmid expressing the nucleoprotein (NP) gene of lymphocytic choriomeningitis virus (LCMV) under the control of the cytomegalovirus promoter. The LCMV NP contains the immunodominant CTL epitope (amino acids 118 to 126) recognized by mice of the H-2d haplotype. After three injections with 200 micrograms of NP DNA, the vaccinated mice were challenged with LCMV variants (clones 13 and 28b) that establish persistent infection in naive adult mice. Fifty percent of the DNA-vaccinated mice were protected, as evidenced by decreased levels of infectious virus in the blood and tissues, eventual clearance of viral antigen from all organs tested, the presence of an enhanced LCMV-specific CD8+ CTL response, and maintenance of memory CTL after clearance of virus infection. However, it should be noted that protection was seen in only half of the vaccinated mice, and we were unable to directly measure virus-specific immune responses in any of the DNA-vaccinated mice prior to LCMV challenge. Thus, at least in the system that we have used, gene immunization was a suboptimal method of inducing protective immunity and was several orders of magnitude less efficient than vaccination with live virus. In conclusion, our results show that DNA immunization works against a persistent viral infection but that efforts should be directed towards improving this novel method of vaccination.

MeSH Terms
3T3 Cells Animals DNA, Viral/administration & dosage Haplotypes Lymphocytic Choriomeningitis/immunology,prevention & control Lymphocytic choriomeningitis virus/genetics Mice Mice, Inbred BALB C Nucleoproteins/genetics Promoter Regions, Genetic Vaccination Viral Vaccines/administration & dosage
Chemicals
DNA, Viral Nucleoproteins Viral Vaccines
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Martins L P
Department of Microbiology and Immunology, UCLA School of Medicine 90024-1747.
Lau L L
Asano M S
Ahmed R
References (62)
62 references, click to expand
  1. The provocation of latent lymphocytic choriomeningitis virus infections in mice by treatment with antilymphocytic serum.
    J Exp Med. 1968 Feb 1;127(2):327-39 PMID: 4965698
  2. Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus.
    Virology. 1994 Feb 15;199(1):132-40 PMID: 8116236
  3. H-2 compatibility requirement for virus-specific T cell-mediated effector functions in vivo. I. Specificity of T cells conferring antiviral protection against lymphocytic choriomeningitis virus is associated with H-2K and H-2D.
    J Immunol. 1976 Nov;117(5 Pt 1):1495-502 PMID: 794412
  4. The virology and immunobiology of lymphocytic choriomeningitis virus infection.
    Adv Immunol. 1980;30:275-331 PMID: 6160740
  5. Convenient assay for interferons.
    J Virol. 1981 Feb;37(2):755-8 PMID: 6163873
  6. Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells.
    Mol Cell Biol. 1982 Sep;2(9):1044-51 PMID: 6960240
  7. Selection of genetic variants of lymphocytic choriomeningitis virus in spleens of persistently infected mice. Role in suppression of cytotoxic T lymphocyte response and viral persistence.
    J Exp Med. 1984 Aug 1;160(2):521-40 PMID: 6332167
  8. Biology of cloned cytotoxic T lymphocytes specific for lymphocytic choriomeningitis virus: clearance of virus in vivo.
    J Virol. 1984 Sep;51(3):682-6 PMID: 6332201
  9. Mechanism of recovery from acute virus infection. I. Role of T lymphocytes in the clearance of lymphocytic choriomeningitis virus from spleens of mice.
    J Immunol. 1985 Jan;134(1):608-15 PMID: 3871115
  10. Cytoimmunotherapy for persistent virus infection reveals a unique clearance pattern from the central nervous system.
    Nature. 1986 May 15-21;321(6067):239-43 PMID: 3086743
  11. Molecular characterization of the genomic S RNA segment from lymphocytic choriomeningitis virus.
    Virology. 1987 Mar;157(1):145-55 PMID: 3824905
  12. Mechanism of recovery from acute virus infection: treatment of lymphocytic choriomeningitis virus-infected mice with monoclonal antibodies reveals that Lyt-2+ T lymphocytes mediate clearance of virus and regulate the antiviral antibody response.
    J Virol. 1987 Jun;61(6):1867-74 PMID: 3494855
  13. High-efficiency transformation of mammalian cells by plasmid DNA.
    Mol Cell Biol. 1987 Aug;7(8):2745-52 PMID: 3670292
  14. Immune therapy of a persistent and disseminated viral infection.
    J Virol. 1987 Dec;61(12):3920-9 PMID: 3682061
  15. Effective clearance of a persistent viral infection requires cooperation between virus-specific Lyt2+ T cells and nonspecific bone marrow-derived cells.
    J Virol. 1987 Dec;61(12):3930-7 PMID: 3500329
  16. Molecular definition of a major cytotoxic T-lymphocyte epitope in the glycoprotein of lymphocytic choriomeningitis virus.
    J Virol. 1988 Mar;62(3):687-95 PMID: 2448497
  17. Analyses of the cytotoxic T lymphocyte responses to glycoprotein and nucleoprotein components of lymphocytic choriomeningitis virus.
    Virology. 1988 Feb;162(2):321-7 PMID: 3257596
  18. T-cell tolerance: exposure to virus in utero does not cause a permanent deletion of specific T cells.
    Proc Natl Acad Sci U S A. 1988 Apr;85(7):2265-8 PMID: 3258424
  19. Organ-specific selection of viral variants during chronic infection.
    J Exp Med. 1988 May 1;167(5):1719-24 PMID: 3367096
  20. Virus-lymphocyte interactions. III. Biologic parameters of a virus variant that fails to generate CTL and establishes persistent infection in immunocompetent hosts.
    Virology. 1988 Jun;164(2):507-16 PMID: 2967012
  21. Virus-lymphocyte interactions. IV. Molecular characterization of LCMV Armstrong (CTL+) small genomic segment and that of its variant, Clone 13 (CTL-).
    Virology. 1988 Jun;164(2):517-22 PMID: 3259346
  22. Plasmid DNA is superior to viral vectors for direct gene transfer into adult mouse skeletal muscle.
    Hum Gene Ther. 1993 Dec;4(6):733-40 PMID: 8186288
  23. Cytotoxic T-cell memory without antigen.
    Nature. 1994 Jun 23;369(6482):648-52 PMID: 7516038
  24. Production of monoclonal antibodies by genetic immunization.
    Biotechniques. 1994 Apr;16(4):616-8, 620 PMID: 8024780
  25. CD8+ T lymphocyte-mediated antiviral immunity in mice as a result of injection of recombinant viral proteins.
    J Immunol. 1994 Sep 15;153(6):2554-61 PMID: 8077665
  26. Direct gene transfer into mouse muscle in vivo.
    Science. 1990 Mar 23;247(4949 Pt 1):1465-8 PMID: 1690918
  27. Vaccination and protection from a lethal viral infection: identification, incorporation, and use of a cytotoxic T lymphocyte glycoprotein epitope.
    Virology. 1990 Oct;178(2):393-400 PMID: 1699348
  28. Peptide-induced antiviral protection by cytotoxic T cells.
    Proc Natl Acad Sci U S A. 1991 Feb 1;88(3):991-3 PMID: 1992491
  29. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation.
    J Exp Med. 1991 Mar 1;173(3):721-30 PMID: 1847722
  30. Molecular basis of viral persistence: a single amino acid change in the glycoprotein of lymphocytic choriomeningitis virus is associated with suppression of the antiviral cytotoxic T-lymphocyte response and establishment of persistence.
    J Virol. 1991 Apr;65(4):1863-9 PMID: 1840619
  31. Infection of lymphocytes by a virus that aborts cytotoxic T lymphocyte activity and establishes persistent infection.
    J Exp Med. 1991 Jul 1;174(1):203-12 PMID: 1905339
  32. Localization of the influenza virus nucleoprotein: cell-associated and extracellular non-virion forms.
    J Gen Virol. 1991 Jul;72 ( Pt 7):1699-702 PMID: 1856696
  33. Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs.
    Nature. 1991 Aug 29;352(6338):815-8 PMID: 1881437
  34. Conditions affecting direct gene transfer into rodent muscle in vivo.
    Biotechniques. 1991 Oct;11(4):474-85 PMID: 1793583
  35. Genetic immunization is a simple method for eliciting an immune response.
    Nature. 1992 Mar 12;356(6365):152-4 PMID: 1545867
  36. Heterologous protection against influenza by injection of DNA encoding a viral protein.
    Science. 1993 Mar 19;259(5102):1745-9 PMID: 8456302
  37. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells.
    Nature. 1993 Apr 22;362(6422):758-61 PMID: 8469287
  38. The role of the CD28 receptor during T cell responses to antigen.
    Annu Rev Immunol. 1993;11:191-212 PMID: 8386518
  39. Gene inoculation generates immune responses against human immunodeficiency virus type 1.
    Proc Natl Acad Sci U S A. 1993 May 1;90(9):4156-60 PMID: 8483929
  40. Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle.
    Hum Mol Genet. 1992 Sep;1(6):363-9 PMID: 1301910
  41. Direct gene transfer into skeletal muscle in vivo: factors affecting efficiency of transfer and stability of expression.
    Hum Gene Ther. 1993 Apr;4(2):151-9 PMID: 8494924
  42. Vaccination to prevent persistent viral infection.
    J Virol. 1993 Jul;67(7):4372-8 PMID: 8510226
  43. Systemic gene expression after intravenous DNA delivery into adult mice.
    Science. 1993 Jul 9;261(5118):209-11 PMID: 7687073
  44. Virus-induced immunosuppression. 1. Age at infection relates to a selective or generalized defect.
    Virology. 1993 Aug;195(2):397-405 PMID: 8393233
  45. In vivo gene delivery. Efficient transfection of T lymphocytes in adult mice.
    J Biol Chem. 1993 Aug 5;268(22):16087-90 PMID: 8344890
  46. Bovine herpesvirus 1: immune responses in mice and cattle injected with plasmid DNA.
    J Virol. 1993 Sep;67(9):5664-7 PMID: 8350420
  47. Gene therapy by intramuscular injection of plasmid DNA: studies on firefly luciferase gene expression in mice.
    Hum Gene Ther. 1993 Aug;4(4):419-31 PMID: 8399489
  48. Heterologous and homologous protection against influenza A by DNA vaccination: optimization of DNA vectors.
    DNA Cell Biol. 1993 Nov;12(9):777-83 PMID: 8216848
  49. Molecular determinants of macrophage tropism and viral persistence: importance of single amino acid changes in the polymerase and glycoprotein of lymphocytic choriomeningitis virus.
    J Virol. 1993 Dec;67(12):7340-9 PMID: 7693969
  50. Identification of an alternative CTLA-4 ligand costimulatory for T cell activation.
    Science. 1993 Nov 5;262(5135):905-7 PMID: 7694361
  51. Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice.
    Science. 1993 Nov 5;262(5135):907-9 PMID: 7694362
  52. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations.
    Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11478-82 PMID: 8265577
  53. Virus-induced immunosuppression: a murine model of susceptibility to opportunistic infection.
    J Infect Dis. 1988 Jul;158(1):232-5 PMID: 3392416
  54. Genetic analysis of in vivo-selected viral variants causing chronic infection: importance of mutation in the L RNA segment of lymphocytic choriomeningitis virus.
    J Virol. 1988 Sep;62(9):3301-8 PMID: 3261347
  55. Fine dissection of a nine amino acid glycoprotein epitope, a major determinant recognized by lymphocytic choriomeningitis virus-specific class I-restricted H-2Db cytotoxic T lymphocytes.
    J Exp Med. 1988 Aug 1;168(2):559-70 PMID: 2457647
  56. Anti-viral protection and prevention of lymphocytic choriomeningitis or of the local footpad swelling reaction in mice by immunization with vaccinia-recombinant virus expressing LCMV-WE nucleoprotein or glycoprotein.
    Eur J Immunol. 1989 Mar;19(3):417-24 PMID: 2468501
  57. Molecular analyses of a five-amino-acid cytotoxic T-lymphocyte (CTL) epitope: an immunodominant region which induces nonreciprocal CTL cross-reactivity.
    J Virol. 1989 Oct;63(10):4303-10 PMID: 2476570
  58. Molecularly engineered vaccine which expresses an immunodominant T-cell epitope induces cytotoxic T lymphocytes that confer protection from lethal virus infection.
    J Virol. 1989 Oct;63(10):4311-6 PMID: 2476571
  59. Major histocompatibility complex--dependent T cell epitopes of lymphocytic choriomeningitis virus nucleoprotein and their protective capacity against viral disease.
    Eur J Immunol. 1989 Sep;19(9):1657-67 PMID: 2477254
  60. The completed sequence of lymphocytic choriomeningitis virus reveals a unique RNA structure and a gene for a zinc finger protein.
    Virology. 1989 Nov;173(1):1-10 PMID: 2510401
  61. DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody.
    Hum Mol Genet. 1993 Nov;2(11):1847-51 PMID: 8281146
  62. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system.
    Nature. 1974 Apr 19;248(5450):701-2 PMID: 4133807
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
Published
1995-04-00
Pages
2574-82
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC188935
Subset
IM
Grants
NIAID NIH HHS · AI-30048 · United States
NINDS NIH HHS · NS-21496 · United States
NIAID NIH HHS · T32AI07-388 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com